{"id":58118,"date":"2023-09-27T19:01:21","date_gmt":"2023-09-27T17:01:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/"},"modified":"2023-09-27T19:01:21","modified_gmt":"2023-09-27T17:01:21","slug":"ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/","title":{"rendered":"OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update"},"content":{"rendered":"<div>\n<p>\n<b><span class=\"bwuline\">Financial highlights<\/span><\/b><\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230927782139\/en\/545518\/5\/OSE_LOGO_Horizontal_RVB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230927782139\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20230927782139\/en\/545518\/5\/OSE_LOGO_Horizontal_RVB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230927782139\/en\/545518\/22\/OSE_LOGO_Horizontal_RVB.jpg\"><\/a><\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Financial visibility secured over the next 12 months, until Q4 2024, supported by additive financing secured in H1-2023 and reduction of operating expenses.<\/b><\/li>\n<li>\n<b>\u20ac15 million available cash as of June 30, 2023, supplemented by R&amp;D tax credit of \u20ac5.4 million and additive financing secured post-H1-2023 for almost \u20ac14 million, including a capital increase of \u20ac11.6 million driven by the bridge financing announced in Q2 2023 and amended <sup>(1)<\/sup> in September 2023 to support clinical programs.<\/b><\/li>\n<\/ul>\n<p>\n<b><span class=\"bwuline\">Clinical pipeline highlights<\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Tedopi\u00ae (T-cell specific immunotherapy &#8211; cancer vaccine): Based on final results of positive data on survival, safety and quality of life from the first Phase 3 trial in 3<sup>rd<\/sup> line in non-small cell lung cancer published in the international leading medical journal \u2018Annals of Oncology\u2019, confirmatory Phase 3 in preparation for 2024 in 2<sup>nd<\/sup> line, combined with a strategy of unique companion diagnostic development. Completion of patient enrollment in the Phase 2 in pancreatic cancer announced in May 2023, clinical readout expected in 2024.<\/b><\/li>\n<li>\n<b>OSE-127\/Lusvertikimab (IL-7R antagonist antibody): Phase 2 in ulcerative colitis with last patient enrollment expected in Q4 2023 and top-line results in the next months.<\/b><\/li>\n<li>\n<b>OSE-172\/BI765063 (SIRP\u03b1 antagonist antibody): Ongoing clinical expansion trial in advanced solid tumors by Boehringer Ingelheim.<\/b><\/li>\n<li>\n<b>FR104\/VEL-101 (CD28 antagonist antibody): Ongoing Phase 1\/2 study in kidney transplantation with last patient enrollment completed in July 2023. International Phase 2 study in kidney transplantation under preparation by Veloxis.<\/b><\/li>\n<li>\n<b>OSE-279 (PD1 antagonist antibody): Phase 1\/2 clinical trial in solid tumors and lymphomas initiated in Q4 2022. First clinical results will be presented in international conference in October 2023.<\/b><\/li>\n<\/ul>\n<p>NANTES, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:<\/p>\n<p>\n<b>OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) <\/b>today announces its consolidated half-year financial results and provides updates on key milestones achieved during H1 2023 as well as the Company\u2019s outlook for its immunotherapies in immuno-oncology and immuno-inflammation.<\/p>\n<p>\n<b>Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics comments:<\/b> <i>\u201cOSE\u2019s key priorities for 2023 and beyond will lie in the successful conduct of the new Tedopi\u00ae pivotal Phase 3 program, along with the maximization of the near-term value of Lusvertikimab while strengthening our partnership business-model assuring recurrent revenues from our first-in-class programs. The full funding of these strategic programs will be secured in due course through additional financial resources to deliver on our goals for the benefit of both the patients and our stakeholders.<\/i> <i>OSE has today a solid late-stage clinical and preclinical diversified portfolio in immuno-oncology (IO) and immuno-inflammation (I&amp;I). The increased interest of the scientific and medical community in cancer vaccine, in particular Tedopi\u00ae, encourages us to stay strategically focused and committed to make our drug candidate available to all eligible cancer patients in secondary resistance. We also look forward to the Lusvertikimab Phase 2 data readouts in ulcerative colitis in the next months and to generate additive value in both I&amp;I and IO with our pre-IND OSE-230 and BiCKI\u00ae-IL7 programs. In parallel, at research level, we will continue to strengthen our first-in-kind platform built at the intersection of Antibody Engineering, Data Science, Artificial Intelligence (AI) and novel RNA Therapeutics technologies which is generating exciting clinical opportunities for future next-generation immunotherapies.\u201d<\/i><\/p>\n<p>\n<b>Anne-Laure Autret-Cornet, Chief Financial Officer of OSE Immunotherapeutics, adds: <\/b><i>\u201cWe have strengthened our cash position and secured new financing in H1-2023 to extend our financial visibility for over the next 12 months. In parallel, we significantly reduced our cash burn compared to last year after a strict review of strategic expenses and prioritization for out-licensing. This financial strategy allows us to pursue strategic investments on Tedopi\u00ae and Lusvertikimab while pursuing innovative research programs to increase their value and interests. Our force is based on our recurrent \u20ac20 million average annual turnover these last 5 years, driven mainly by collaborations and licensing agreements with pharma companies. This business model based mostly on non-dilutive revenues remains our priority and will be further reinforced.\u201d<\/i><\/p>\n<p>\n<b>CLINICAL PROGRESS IN IMMUNO-ONCOLOGY AND IMMUNO-INFLAMMATION<\/b><\/p>\n<p>\n<b>PROPRIETARY ASSETS<\/b><\/p>\n<p>\n<b>Tedopi\u00ae, T-cell epitope-based therapeutic cancer vaccine<\/b><\/p>\n<p>\n<b><i>Most advanced therapeutic cancer vaccine in clinical development. Confirmatory Phase 3 study with a companion diagnostic strategy under preparation to support the registration of Tedopi\u00ae as a potential new standard of care in second line for non-small cell lung cancer (NSCLC) patients in secondary resistance to immune checkpoint inhibitors (ICI) based on positive regulatory advice from FDA and EMA; Authorizations for compassionate use in NSCLC in third line in France, Italy and Spain.<\/i><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn September, positive Phase 3 data from Tedopi\u00ae in HLA-A2 lung cancer patients with resistance to previous immunotherapy were published in the peer-reviewed journal \u2019Annals of Oncology\u2019.<\/li>\n<li>\nIn July, the United States Patent and Trademark Office granted a new patent protecting Tedopi\u00ae for its use in cancer patients after failure with PD1\/PD-L1 immune checkpoint inhibitor treatment and providing protection until year 2037 in the US.<\/li>\n<li>\nIn June, the Company received \u20ac1.5 million in funding from Bpifrance for the development of a companion diagnostic for Tedopi\u00ae in NSCLC. This test will be used to identify HLA-A2 positive NSCLC patients eligible for treatment with Tedopi\u00ae in the next pivotal Phase 3 clinical trial under preparation.<\/li>\n<li>\nIn June, OSE Immunotherapeutics presented a poster at the ASCO (American Society of Clinical Oncology) annual meeting showing new data on prognostic factors of overall survival from the ATALANTE-1 Phase 3 study in NSCLC highlighting the correlation between Tedopi\u00ae\u2019s mechanism of action and patients\u2019 overall survival.<\/li>\n<li>\nIn May, patient enrollment was completed in TEDOPaM Phase 2 clinical trial (sponsored by the oncology group GERCOR) evaluating Tedopi\u00ae in advanced pancreatic cancer. A total of 136 patients were recruited and the final results are expected in 2024.<\/li>\n<li>\nIn March, the Spanish Drug Agency has made a new early access program available allowing access to Tedopi\u00ae through a Special Situation Authorization <sup>(1)<\/sup> in the treatment of advanced or metastatic NSCLC after ICI failure. This Special Situation Authorization was based on the positive clinical data from the initial Phase 3 trial of Tedopi\u00ae (ATALANTE-1) in third line treatment and the high unmet need for these patients.<\/li>\n<\/ul>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<sup>(1)<\/sup><\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p>\n<i>The Special Situation Authorization (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.boe.es%2Fbuscar%2Fdoc.php%3Fid%3DBOE-A-2009-12002&amp;esheet=53564809&amp;newsitemid=20230927782139&amp;lan=en-US&amp;anchor=Real+Decreto+1015%2F2009&amp;index=1&amp;md5=f210793d23f2211ad86058908e506279\" rel=\"nofollow noopener\" shape=\"rect\">Real Decreto 1015\/2009<\/a>) is intended to provide early access to medicines for patients with a severe or rare disease with high unmet need and for which no authorized therapeutic alternatives are available.<\/i><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Lusvertikimab (OSE-127), IL-7 Receptor (IL-7R) antagonist<\/b><\/p>\n<p>\n<b><i>Most advanced Interleukin-7 antagonist immunotherapy in clinical development with a strong biological rationale in refractory IBD patients.<\/i><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn July, the trial\u2019s Independent Drug Safety Monitoring Board (DSMB) provided a positive recommendation on the continuation until its completion of the Phase 2 clinical trial on Lusvertikimab in ulcerative colitis. Last patient enrollment is expected for Q4 2023.<\/li>\n<li>\nIn July, positive opinion for Orphan Drug Designation was granted by the European Medicines Agency to Lusvertikimab in the treatment of Acute Lymphoblastic Leukemia based on preclinical results presented and awarded at last American Society of Hematology (ASH) annual conference (December 2022) in New Orleans (US).<\/li>\n<li>\nIn May, OSE Immunotherapeutics earned the full worldwide rights on Lusvertikimab for all indications.<\/li>\n<li>\nIn March, positive Phase 1 results on Lusvertikimab for the treatment of chronic autoimmune diseases were published and selected as \u2018Top Read\u2019 in the peer-reviewed journal \u201cJournal of Immunology\u201d.<\/li>\n<\/ul>\n<p>\n<b>OSE-279, proprietary PD1 antagonist<\/b><\/p>\n<p>\n<b><i>High affinity PD1 antibody, recent patent granted in US, Europe, China, Japan<\/i><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn December 2022, first patient dosed in a Phase 1\/2 clinical trial in patients with advanced solid tumors or lymphomas.<\/li>\n<li>\nFirst clinical data will be presented at AACR-NCI-EORTC (Boston, 11 \u2013 15th October 2023).<\/li>\n<\/ul>\n<p>\n<b>PARTNERED ASSETS<\/b><\/p>\n<p>\n<b>BI 765063, first-in-class SIRP\u03b1 inhibitor on the SIRP\u03b1\/CD47 myeloid pathway in advanced solid tumors, developed in partnership with Boehringer Ingelheim<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPhase 1b clinical expansion trial initiated in May 2022 with BI 765063, sponsored and conducted by Boehringer Ingelheim in advanced hepatocellular carcinoma and head and neck cancer.<\/li>\n<li>\nIn April, a poster highlighting the predictive response biomarkers from Phase I clinical trial of BI765063, stand-alone and in combination with ezabenlimab, has been presented at the AACR 2023 annual conference (Orlando).<\/li>\n<\/ul>\n<p>\n<b>FR104\/VEL-101, a monoclonal antibody antagonist of CD28, developed in partnership with Veloxis Pharmaceuticals, Inc. in kidney transplantation<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn July, patient enrollment was completed in the FIRsT Phase 1\/2 clinical trial evaluating FR104\/VEL-101 in renal transplantation, sponsored and conducted by the University Hospital of Nantes. A longer-term follow-up assessment will be performed one year after transplantation.<\/li>\n<li>\nInternational Phase 2 clinical trial in kidney transplantation is under preparation by Veloxis.<\/li>\n<\/ul>\n<p>\n<b>RESEARCH PROGRAMS<\/b><\/p>\n<p>\n<b>OSE-230, novel monoclonal antibody to activate a pro-resolutive GPCR target (ChemR23), a novel and innovative approach in the management of the resolution of neutrophil-mediated chronic and severe inflammation<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn July, the second peer-reviewed results on OSE-230 were published in the leading journal \u201cFrontiers in Immunology\u201d after a publication in \u201cSciences Advances\u201d (Trilleaud et al. 2021).<\/li>\n<li>\nIn June, a poster highlighting the innovative mechanism of action on neutrophils and inhibition of the pathogenic NETosis process was presented at the FOCIS 2023 annual conference (Boston).<\/li>\n<\/ul>\n<p>\n<b>CLEC-1, novel myeloid immune checkpoint target in immune-oncology<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn April, two posters reporting the latest research updates on CLEC-1 were presented at the 2023 American Association for Cancer Research (AACR) meeting.<\/li>\n<li>\nIn November 2022, publication in the peer-reviewed journal \u201cSciences Advances\u201d of fundamental discoveries and preclinical results showing that CLEC-1 is a novel myeloid checkpoint interacting with a new ligand and highlighting the therapeutic potential of CLEC-1 antagonist antibodies as innovative cancer immunotherapy.<\/li>\n<\/ul>\n<p>\n<b>BiCKI\u00aeIL-7v, a novel bispecific therapy combining anti-PD-1 and the cytokine IL-7<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn June, an invited oral communication and a poster reporting the differentiated advantages of the IL-7 cytokine to sustain long-term survival and functions of tumor-reactive T lymphocytes were presented at the annual cytokine-based drug development summit (Boston) and at the Antibody Engineering and Therapeutics 2023 Europe conference (Amsterdam).<\/li>\n<\/ul>\n<p>\n<b>Novel RNA Therapeutics &amp; Artificial Intelligence innovative research programs<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nOSE Immunotherapeutics is building a first-in-kind research platform at the intersection of Antibody Engineering, Data Science and Artificial Intelligence (AI) development programs dedicated to monoclonal antibodies (AI programs initiated in 2020 and reinforced in 2021 with the MabSilico collaboration). This cutting-edge platform adds novel RNA Therapeutics and RNA Delivery methods recently patented by our research team to continue to develop next-generation immunotherapy medicines modulating immune cell responses in the field of immuno-inflammation and immuno-oncology.<\/li>\n<li>\nIn August, OSE Immunotherapeutics received a grant from the French Government and Region Pays de la Loire to support the Company\u2019s research programs in the field of RNA Therapeutics.<\/li>\n<\/ul>\n<p>\n<b>CORPORATE GOVERNANCE<\/b><\/p>\n<p>\nEric Leire was appointed independent Director of OSE Immunotherapeutics on June 22, 2023.<\/p>\n<p>\nEric Leire is a Medical Doctor and American and French citizen. He brings a professional international experience, both in the US and in Europe, in listed biotechnology and pharmaceutical companies. He is currently President and Chief Executive Officer of Genflow Biosciences Ltd. Through his active experience in venture capital funds in the health field (Medwell Capital, Canada and Biofund Venture, Denmark), he has contributed to develop biotech companies.<\/p>\n<p>\nNicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, was appointed as Director and Anne-Laure Autret-Cornet, Chief Financial Officer, as Director representing the employee shareholders.<\/p>\n<p>\n<b>H1 2023 RESULTS<\/b><\/p>\n<p>\nThe key figures of the 2023 consolidated half-year results are reported below:<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>In k\u20ac<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignc bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nJune 30, 2023<\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignc bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nJune 30, 2022<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOperating result<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n(13,504)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n(3,425)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet result<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n(11,860)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n(1,979)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>In k\u20ac<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignc bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nJune 30, 2023<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignc bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nDecember 31, 2022<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAvailable cash<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n15,018<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n25,620<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1 bwwidth50\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nConsolidated balance sheet<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n80,391<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc bwwidth25\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n91,781<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nAs of June 30, 2023, available cash amounted to \u20ac15 million, giving a financial visibility until Q4 2024.<\/p>\n<p>\nDuring the first half of 2023, OSE Immunotherapeutics secured:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b><sup>(1)<\/sup> An equity financing line<\/b> with Vester Finance, set up on April 27, 2023. This financing has triggered at the end of September a capital increase of \u20ac11.6 million (without any discount on the share price at the date of signature). To supplement its financial resources and in order to extend its financial visibility until the fourth quarter of 2024, OSE Immunotherapeutics signed on 27 September 2023, an extension to this equity financing line agreement with Vester Finance, at the same conditions<sup>1<\/sup>.<\/p>\n<p>This extension, approved by the Board of Directors of September 27, 2023, acting on delegation from the general assembly meeting of shareholders of June 22, 2023<sup>2<\/sup>, relates to a maximum of 900,000 shares of the Company, representing a maximum of 4,16% of the share capital, that Vester committed to subscribe on its own initiative, over a maximum period of 24 months, subject to certain usual contractual conditions.<\/p>\n<p>Assuming that the totality of this additional line of financing is used in full, a shareholder holding 1.00% of the capital of OSE Immunotherapeutics before its establishment, would see his stake increase to 0.96% of the capital on an undiluted basis<sup>3<\/sup> and 0.96% of the share capital on a diluted basis<sup>4<\/sup>.<\/p>\n<p>This transaction does not give rise to the preparation of a prospectus subject to the approval of the \u201cAutorit\u00e9 des March\u00e9s Financiers,\u201d based on Article 1 of the Prospectus Regulation granting an exemption when a transaction relates to a dilution less than 20% of the Company&#8217;s share capital.<\/p>\n<p>The number of shares issued under this agreement and admitted to trading will be communicated monthly on the Company&#8217;s website.<br \/>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Loans and \u201cPGE Resilience<\/b>\u201d<\/p>\n<p>The Company obtained the formal agreement on loans for a total amount of \u20ac5.3 million with the collective support of \u201cLa R\u00e9gion Pays de la Loire,\u201d Bpifrance and its banking pool composed by banks CIC, Cr\u00e9dit Mutuel and BNP to finance its strategic R&amp;D programs. Favorable conditions were granted for these loans, with an interest range of 2-4% and reimbursement timelines within 3 to 5 years. Part of these loans is composed by a \u201cPGE Resilience\u201d (&#8220;Pr\u00eat Garanti par l\u2019\u00c9tat&#8221;) loan guaranteed by the French State, implemented in the context of the Ukrainian crisis.<\/p>\n<p>At the end of June 2023, \u20ac3.1 million have been drawdown. The balance has been received in Q3 2023.<br \/>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n\u20ac1.5 million in<b> funding from Bpifrance<\/b> for the development of a companion diagnostic for the cancer vaccine Tedopi\u00ae in non-small cell lung cancer.<\/li>\n<\/ul>\n<p>\nThis available cash will enable the Company to finance its clinical development and R&amp;D costs for earlier stage products.<\/p>\n<p>\nDuring the first half of 2023, the Company recorded a consolidated net result of \u20ac-11,9 million.<\/p>\n<p>\nCurrent operating expenses were \u20ac14.9 million (versus \u20ac19.4 million for the same period in 2022) of which 77% are related to R&amp;D. After a strategic review of costs and programs, operating expenses dropped dawn by 25% compared to H1 2022.<\/p>\n<p>\nThe Board of Directors of September 27, 2023, has approved the Company\u2019s semester accounts as of June 30, 2023. The full \u201cHalf-year financial report\u201d (Regulated information) is available on: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ose-immuno.com%2Fen%2Ffinancial-documents%2F&amp;esheet=53564809&amp;newsitemid=20230927782139&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.ose-immuno.com%2Fen%2Ffinancial-documents%2F&amp;index=2&amp;md5=5726fc2064093b71355004d340e93bf7\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.ose-immuno.com\/en\/financial-documents\/<\/a>. The limited review procedures on the consolidated accounts have been performed. The report on this limited review is being issued.<\/p>\n<p class=\"bwalignc\">\n<b><i>CONSOLIDATED PROFIT &amp; LOSS<\/i><\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrowaltcolor0 bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>In K\u20ac<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>H1 2023<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>H1 2022<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwsinglebottom bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTurnover<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1,358<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n16,047<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>OPERATING INCOME &#8211; RECURRING<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>1,358<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>16,047<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nResearch &amp; Development expenses<\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(9,693)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(14,395)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOverhead expenses<\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(3,604)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(3,813)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwsinglebottom bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nExpenses related to share-based payments<\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(1,562)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(1,182)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>OPERATING PROFIT\/LOSS &#8211; RECURRING<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(13,501)<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(3,341)<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwsinglebottom bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOther operating income and expenses<\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(4)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(84)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>OPERATING RESULT<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(13,504)<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(3,425)<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFinancial income<\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2,658<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2,023<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwsinglebottom bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFinancial expenses<\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(1,608)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(708)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>PROFIT\/LOSS BEFORE TAX<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(11,943)<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(2,110)<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>INCOME TAX<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>84<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>132<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrowaltcolor0 bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>CONSOLIDATED NET RESULT<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(11,860)<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(1,979)<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b><i>Of which consolidated net result attributable to shareholders<\/i><\/b><\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b><i>(11,860)<\/i><\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b><i>(1,979)<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet earnings attributable to shareholders<\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nWeighted average number of shares outstanding<\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n18,624,665<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n18,527,401<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<ul class=\"bwlistdisc\">\n<li>\nThe basic and diluted result per common share (\u20ac\/share)<\/li>\n<\/ul>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0,64)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0,11)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwsinglebottom bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<ul class=\"bwlistdisc\">\n<li>\nDiluted result per share<\/li>\n<\/ul>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0,64)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0,11)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrowaltcolor0 bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>In K\u20ac<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>H1 2023<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>H1 2022<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>NET RESULT<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(11,860)<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(1,979)<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Amounts to be recycled in the income statement:<\/i><\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUnrealized gains on securities available for sale, net of tax<\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCurrency conversion difference<\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(7)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n46<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Amounts not to be recycled in the income statement:<\/i><\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nActuarial gains and losses on post-employment benefits<\/p>\n<\/td>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n0<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n34<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwsinglebottom bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOther comprehensive income in the period<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(7)<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(13)<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrowaltcolor0 bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>GLOBAL PROFIT\/LOSS<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(11,867)<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(1,992)<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p class=\"bwalignc\">\n<b><i>CONSOLIDATED BALANCE SHEET<\/i><\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrowaltcolor0 bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>ASSETS in K\u20ac<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>June 30, 2023<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>December 31, 2022<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>NON-CURRENT ASSETS<\/b><\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAcquired R&amp;D costs<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n47,604<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n48,784<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTangible assets<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n589<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n743<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRights of use<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,712<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4,236<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFinancial assets<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n587<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n635<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwsinglebottom bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDeferred tax assets<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n184<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n182<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrowaltcolor0 bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b><i>TOTAL NON-CURRENT ASSETS<\/i><\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b><i>52,676<\/i><\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b><i>54,581<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>CURRENT ASSETS<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTrade receivables<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n234<\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwpadl0 bwpadr0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n403<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOther current assets<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n12,463<\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwpadl0 bwpadr0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n11,177<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwrightsingle bwpadl0 bwsinglebottom bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCash and cash equivalents<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n15,018<\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n25,620<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrowaltcolor0 bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b><i>TOTAL CURRENT ASSETS<\/i><\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b><i>27,714<\/i><\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b><i>37,200<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrowaltcolor0 bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>TOTAL ASSETS<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>80,391<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>91,781<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwsinglebottom bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrowaltcolor0 bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>EQUITY &amp; LIABILITIES in K\u20ac<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwrightsingle bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>June 30, 2023<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>December 31, 2022<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>SHAREHOLDERS\u2019 EQUITY<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nStated capital<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,806<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,705<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nShare premium<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n39,169<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n38,784<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMerger premium<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n26,827<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n26,827<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTreasury stock<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(483)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(549)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwrightsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nReserves and retained earnings<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(34,932)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(18,349)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwpadl0 bwsinglebottom bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nConsolidated result<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(11,860)<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(17,760)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrowaltcolor0 bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b><i>TOTAL SHAREHOLDERS\u2019 EQUITY<\/i><\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b><i>22,529<\/i><\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b><i>32,658<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwrightsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>NON-CURRENT DEBTS<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwrightsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNon-current financial liabilities<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\nLease non current liabilities<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n34,310<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n37,231<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNon-current lease liabilities<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,157<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,586<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNon-current deferred tax liabilities<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1,430<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1,514<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwsinglebottom bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNon-current provisions<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n423<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n524<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrowaltcolor0 bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b><i>TOTAL NON-CURRENT DEBTS<\/i><\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b><i>39,320<\/i><\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b><i>42,856<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>CURRENT DEBTS<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwrightsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCurrent financial liabilities<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n5,433<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,093<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwrightsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCurrent lease liabilities<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n858<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n883<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwrightsingle bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTrade payables<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n9,421<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n8,539<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCorporate income tax liabilities<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n18<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n21<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwleftsingle bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSocial and tax payables<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2,662<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2,916<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwleftsingle bwpadl0 bwsinglebottom bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOther debts and accruals<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n151<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n816<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrowaltcolor0 bwpadl0 bwrightsingle bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b><i>TOTAL CURRENT DEBTS<\/i><\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b><i>18,542<\/i><\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b><i>16,268<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>TOTAL LIABILITIES<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>80,391<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>91,781<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>ABOUT OSE Immunotherapeutics<\/b><\/p>\n<p>\nOSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology and immuno-inflammation.<\/p>\n<p>\nThe Company\u2019s current well-balanced first-in-class clinical pipeline includes:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Tedopi\u00ae<\/b> (immunotherapy activating tumor specific T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is the Company\u2019s most advanced product; positive results from the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure. Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi\u00ae in combination are ongoing in solid tumors.<\/li>\n<li>\n<b>OSE-279 <\/b>(anti-PD1): ongoing Phase 1\/2 in solid tumors or lymphomas (first patient included). OSE-279 is the backbone therapy of the BiCKI\u00ae platform.<\/li>\n<li>\n<b>OSE-127<\/b> &#8211; <i>lusvertikimab<\/i> (humanized monoclonal antibody antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis (sponsor OSE Immunotherapeutics); ongoing preclinical research in leukemia (OSE Immunotherapeutics).<\/li>\n<li>\n<b>FR-104\/VEL-101 <\/b>(anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1\/2 in renal transplant (sponsor Nantes University Hospital); Phase 1 ongoing in the US (sponsor Veloxis Pharmaceuticals, Inc.).<\/li>\n<li>\n<b>OSE-172\/BI 765063<\/b> (anti-SIRP\u03b1 monoclonal antibody on CD47\/SIRP\u03b1 pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results in monotherapy and in combination, in particular with anti-PD-1 antibody ezabenlimab; international Phase 1b ongoing clinical trial in combination with ezabenlimab alone or with other drugs in patients with recurrent\/metastatic head and neck squamous cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC).<\/li>\n<\/ul>\n<p>\nOSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>BiCKI\u00ae platform<\/b> focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. BiCKI-IL-7 is the most advanced BiCKI\u00ae candidate targeting anti-PD1xIL-7.<\/li>\n<li>\n<b>Myeloid platform<\/b> focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&amp;I). <b>OSE-230 <\/b>(ChemR23 agonist mAb) is the most advanced candidate generated by the platform, with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.<\/li>\n<\/ul>\n<p>\nAdditional information about OSE Immunotherapeutics assets is available on the Company\u2019s website: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ose-immuno.com&amp;esheet=53564809&amp;newsitemid=20230927782139&amp;lan=en-US&amp;anchor=www.ose-immuno.com&amp;index=3&amp;md5=92e05a6bdb7235b35aba711dd4ca2c04\" rel=\"nofollow noopener\" shape=\"rect\">www.ose-immuno.com<\/a><\/p>\n<p>\nClick and follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FOSEIMMUNO&amp;esheet=53564809&amp;newsitemid=20230927782139&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=054b9a20d92211d29e1fb24fbf2dac58\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2F10929673&amp;esheet=53564809&amp;newsitemid=20230927782139&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=932253e469a133776d4edc34bb9be34e\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.<\/p>\n<p>\n<b>Forward-looking statements<\/b><\/p>\n<p>\nThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics\u2019 management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.<\/p>\n<p>\nThese forward-looking statements include statements typically using conditional and containing verbs such as \u201cexpect,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ctarget,\u201d \u201cplan,\u201d or \u201cestimate,\u201d their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics\u2019 shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>OSE Immunotherapeutics<\/b><br \/>Sylvie D\u00e9try<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;:&#x73;y&#x6c;v&#105;&#x65;&#46;&#x64;&#101;&#x74;&#114;&#x79;&#64;&#x6f;s&#x65;-&#105;&#x6d;&#109;&#x75;&#110;&#x6f;&#46;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x73;&#x79;&#x6c;&#x76;&#105;&#101;&#46;&#100;etr&#x79;&#x40;&#x6f;&#x73;&#x65;&#45;&#105;&#109;mun&#x6f;&#x2e;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<p>\nNicolas Poirier<br \/>\n<br \/>Chief Executive Officer<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#105;&#x6c;&#x74;&#111;&#58;&#x6e;&#x69;&#99;&#111;&#x6c;&#x61;&#115;&#46;&#x70;&#x6f;&#105;&#114;&#x69;&#x65;&#114;&#64;&#x6f;&#x73;&#101;&#45;&#x69;&#x6d;&#109;&#117;&#x6e;&#x6f;&#46;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#110;&#x69;&#99;&#x6f;&#108;&#x61;&#115;&#x2e;p&#x6f;i&#x72;i&#x65;r&#64;&#x6f;&#115;&#x65;&#45;&#x69;&#109;&#x6d;&#117;&#x6e;o&#x2e;c&#x6f;m<\/a><\/p>\n<p>\n<b>French Media: FP2COM<\/b><br \/>Florence Portejoie<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x66;&#x70;&#111;r&#x74;&#x65;&#106;o&#x69;&#x65;&#64;f&#x70;&#50;&#99;o&#x6d;&#46;f&#x72;\" rel=\"nofollow noopener\" shape=\"rect\">&#x66;&#112;o&#x72;&#116;&#101;&#x6a;&#x6f;&#105;e&#x40;&#102;p&#x32;&#x63;&#111;m&#x2e;&#102;r<\/a><br \/>+33 6 07 768 283<\/p>\n<p> <a href=\"http:\/\/www.businesswire.com\/news\/home\/20230927782139\/en\/OSE-Immunotherapeutics-Announces-H1-2023-Results-and-Provides-Corporate-Update\/?feedref=Zd8jjkgYuzBwDixoAdXmJgT1albrG1Eq4mAeVP392103_ypKzv-7ah0oHKWbnuHnevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxZM7XiMhduiSeKMTNDLRqI_doMC3CVAuyHo5cJ7XfDuvA==\"> Read full story here <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Financial highlights Financial visibility secured over the next 12 months, until Q4 2024, supported by additive financing secured in H1-2023 and reduction of operating expenses. \u20ac15 million available cash as of June 30, 2023, supplemented by R&amp;D tax credit of \u20ac5.4 million and additive financing secured post-H1-2023 for almost \u20ac14 million, including a capital increase &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58118","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Financial highlights Financial visibility secured over the next 12 months, until Q4 2024, supported by additive financing secured in H1-2023 and reduction of operating expenses. \u20ac15 million available cash as of June 30, 2023, supplemented by R&amp;D tax credit of \u20ac5.4 million and additive financing secured post-H1-2023 for almost \u20ac14 million, including a capital increase ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-27T17:01:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230927782139\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update\",\"datePublished\":\"2023-09-27T17:01:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\\\/\"},\"wordCount\":3177,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230927782139\\\/en\\\/545518\\\/21\\\/OSE_LOGO_Horizontal_RVB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\\\/\",\"name\":\"OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230927782139\\\/en\\\/545518\\\/21\\\/OSE_LOGO_Horizontal_RVB.jpg\",\"datePublished\":\"2023-09-27T17:01:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230927782139\\\/en\\\/545518\\\/21\\\/OSE_LOGO_Horizontal_RVB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230927782139\\\/en\\\/545518\\\/21\\\/OSE_LOGO_Horizontal_RVB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update - Pharma Trend","og_description":"Financial highlights Financial visibility secured over the next 12 months, until Q4 2024, supported by additive financing secured in H1-2023 and reduction of operating expenses. \u20ac15 million available cash as of June 30, 2023, supplemented by R&amp;D tax credit of \u20ac5.4 million and additive financing secured post-H1-2023 for almost \u20ac14 million, including a capital increase ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/","og_site_name":"Pharma Trend","article_published_time":"2023-09-27T17:01:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230927782139\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update","datePublished":"2023-09-27T17:01:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/"},"wordCount":3177,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230927782139\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/","url":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/","name":"OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230927782139\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg","datePublished":"2023-09-27T17:01:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230927782139\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230927782139\/en\/545518\/21\/OSE_LOGO_Horizontal_RVB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ose-immunotherapeutics-announces-h1-2023-results-and-provides-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58118"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58118\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}